Sign in with Google
Sign in with Facebook
Sign in with Apple
The Paris Stock Exchange is showing a strong rebound this Monday at mid-session, with the CAC 40 index up 1.06% to reach 8,154.13 points. At the start of a crucial week highlighted by the European Central Bank meeting on Thursday, investors are focusing on growth stocks. European markets are benefiting from renewed optimism despite ongoing uncertainties about monetary policy. Traders will closely monitor the upcoming US economic data this week, particularly the November employment figures, which were delayed due to the budget impasse.
Publicis Groupe stands out as the leader in gains with a remarkable jump of 3.77% to 90.84 euros. The communication giant is benefiting from positive momentum after revising its 2025 organic growth target to the upper range of +5.5% during the presentation of its third-quarter results. The group also reaffirms an operating margin slightly above 18% for the year, while free cash flow is expected to be just over 1.9 billion euros. This performance highlights the resilience of Publicis's business model in a complex macroeconomic environment, with third-quarter revenues reaching 3.529 billion euros, representing a 5.7% increase for the quarter and a 3.1% rise year-on-year. Schneider Electric closely follows with a rise of 2.42% to 241.10 euros, solidifying its position among the session's leaders. The stock benefits from a positive recommendation by Citi, published this Monday, which raised its price target from 280 to 300 euros while maintaining its buy recommendation. The energy technology specialist revealed its ambitious financial targets for 2025-2030 on December 11 during its investor day in London, aiming for an average annual organic sales growth between 7% and 10%.
Luxury stocks also make a significant contribution to the day's performance. Kering is up 3.38% to 306.20 euros, following the announcement of the sale of Kering Beauté to L'Oréal, with completion expected in the first half of 2026. This strategic move, announced last December 11, allows the group to refocus on its flagship brands while generating cash to fund its development. Third-quarter revenues stand at 3.415 billion euros, down 10% year-on-year, reflecting ongoing challenges in the Chinese market. Hermès International is advancing 2.34% to 2,184 euros, confirming its resilience amid sector turbulence. The luxury goods company reaffirms an ambitious target for revenue growth at constant exchange rates, with revenues of 11.9 billion euros for the first nine months of the year, up 9% at constant rates. Saint-Gobain rounds out the top movers with a rise of 2.67% to 88.60 euros. The construction materials specialist benefits from a buy recommendation by Jefferies dated December 12, even though the price target was slightly lowered from 144.50 to 140 euros. The group is targeting an operating margin of over 11.0% in 2025, with third-quarter revenues of 11.42 billion euros, up 1.3% in local currencies. This performance demonstrates the group's ability to maintain growth despite a challenging market environment, particularly in residential construction.
Sanofi experienced the largest drop on the CAC 40, falling 2.33% to 81.38 euros, impacted by Monday's announcement that the US regulatory review process for tolebrutinib will extend beyond the target action date of December 28, 2025, with further guidance expected from the FDA by the end of the first quarter of 2026. This setback occurs despite the French pharmaceutical company confirming sales growth in 2025 at a high single-digit percentage at constant exchange rates, with revenues of 12.434 billion euros in the third quarter, up 7.0% year-on-year. Tolebrutinib is an investigational Bruton tyrosine kinase inhibitor for the treatment of non-relapsing secondary progressive multiple sclerosis. In response to an FDA request, Sanofi has submitted an expanded access protocol for this drug, highlighting the group's commitment to providing eligible patients access to this experimental therapy. This underperformance contrasts with the generally positive trend of the Paris market and illustrates the sensitivity of pharmaceutical stocks to regulatory uncertainties. Other stocks recorded more moderate movements: Edenred dropped 0.91% to 18.43 euros, Thales slipped slightly by 0.30% to 230.40 euros, while Crédit Agricole was almost flat with a slight decrease of 0.12% to 17.095 euros. Pernod Ricard remained nearly stable with a symbolic gain of 0.05% to 76.24 euros. The week promises to be eventful, particularly with the ECB's monetary policy decision on Thursday, which is expected to clarify interest rate prospects for 2026.
S&P 500 edges down 0.19% to 6,963 points, caught between technology and services
Nasdaq Nears Stability at 25,787 Points: DexCom Soars, Semiconductors Plunge
Nasdaq slightly down to 25,741 points as Intel jumps 7% and Adobe falls 5%
This article was automatically translated by AI. The information presented is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any financial instrument, or a solicitation. Readers should conduct their own research before making any decisions. Investing in the stock market involves risks, including the loss of capital. Past performance of an asset or market is not indicative of future results. Any investment decision should take into account your personal financial situation, objectives, and risk tolerance.
